New Delhi [India], April 28 (ANI/PNN): GenWorks Health is one of the leading healthcare solutions providers that uses the power of digitisation for improving specialist access to the last mile. The company strongly believes that it can create a strong impact by connecting all patients to specialists at the need of the hour and also leave no stone unturned in ensuring that. Working on the belief that digital interventions can realign conventional healthcare practices to make them more patient-centric, equitable, and inclusive, GenWorks makes healthcare more accessible and affordable. The G20 Health Working Group is a forum that brings together health experts and policymakers from the world's 20 largest economies to discuss key issues and develop policy recommendations. GenWorks showcased its Connected Care - Digital Health solutions for 11 clinical care areas such as Oncology (Breast and Cervical Screening), Respiratory, Pathology, Radiology, ICU, NICU, Audiology, Cardiology, Nephro
1. Intradialytic exercise for a minimum of 60 minutes during thrice weekly dialysis sessions improves survival rates in adult patients who are receiving hemodialysis Evidence Rating Level:1 (Excellent) Chronic kidney disease is becoming increasingly prevalent worldwide, leading to an exponential increase in the number of individuals experiencing kidney failure requiring kidney-replacement therapy (KRT), which is
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.
1. In this target emulation trial, parathyroidectomy did not affect long-term renal function in adults with primary hyperparathyroidism (PHPT). 2. Patients with parathyroidectomy had no difference in the estimated glomerular filtration rate (eGFR) decline compared to those without parathyroidectomy. Evidence Rating Level: 1 (Excellent) Study Rundown: The definitive treatment for PHPT is parathyroidectomy to remove
With funding from charity Kidney Research UK, Dr Carl May from Bristol Medical School and his team have identified a new treatment pathway for patients with non-genetic (idiopathic) nephrotic syndrome (INS), targeting a still unknown factor that causes the progression towards kidney failure.